RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:标的无直接敞口
北京时间·🕒 发布 02:02:42·⟳ 抓取 02:15:16 +12m34s·⚡ 决策 10-09 02:16:06 +50s·19.3 天前
Edgewise Therapeutics（EWTX）EDG-15400 的 HFpEF 二期试验完成首例患者给药，股价盘中下跌
该消息仅确认临床试验按计划推进，未改变药物成功概率的可交易信息，也没有新增基本面损害；市场反应平淡偏负，做多与做空均无明确正期望。
📄 原文RTTNews Biotech↗ 原文
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Edgewise Therapeutics（EWTX.US）
二期试验首例患者给药是常规研发进度，缺少疗效或商业增量；股价小幅下跌也不构成强空催化，无明确正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Edgewise 的 EDG-15400 仅完成 HFpEF 二期首例给药，属于常规临床进度而非疗效或监管催化。事件不提供可交易的预期差，故回避。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- 首例给药没有二期疗效结果，不能验证EDG-15400的临床有效性或商业价值。
- 报道时股价下跌2.70%，说明市场未将该常规节点视为增量利好。
主要风险
- 若公司同步披露未被RTTNews概括的一期数据细节，可能改变短期情绪；当前正文未显示此类新增结果。
- 临床期小盘生物科技股波动大，但波动本身不构成方向性交易依据。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
正文仅含首例给药、试验设计和即将展示一期数据的安排，没有疗效成功、获批、合作或上调指引。
检索:EDG-15400 Phase 2 first patient dosed efficacy data FDA approval partnership guidance 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-08 · 影响 none
正文未披露临床暂停、失败、安全性事故或公司级负面事实；股价小跌不是经营损害。
检索:EWTX EDG-15400 clinical hold trial failure adverse event safety concern 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺口与事件本身的低预期差共同支持AVOID，而非仅凭缺少先例做空或做多。
方向:未使用外部先例；当前事件并非疗效、批准或交易类催化，常规首例给药的方向参考不足以形成交易edge。
涨幅量级:没有高相似、同市场、同相位且锚点干净的先例用于校准目标涨幅。
形态:不从记忆推断同类事件必然上涨或下跌；本消息的实际盘中反应为小幅下跌。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 20 ms
{"result": "search_processed_events:agent query=`edg-15400 hfpef phase 2 trial first patient dosing | edgewise therapeutics ewtx first patient dosed phase 2 equinox-hfpef edg-15400`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 8,568 字
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down
By
RTTNews Staff Writer
✉
Published:
10/8/2026 2:02 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Edgewise Therapeutics (
EWTX
) announced that the first patient has been dosed in the Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) and a left ventricular ejection fraction of at least 50%.
EDG-15400 is an investigational oral, selective cardiac sarcomere modulator designed to address impaired cardiac relaxation, a key feature of HFpEF that contributes to symptoms and disease burden.
The multicenter, randomized, double-blind, placebo-controlled trial is expected to enroll approximately 90 adults aged 30 to 84 with HFpEF and New York Heart Association class II or III symptoms.
Participants will receive once-daily oral doses of 25 mg or 50 mg of EDG-15400, or placebo, for up to 12 weeks. The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics.
Edgewise Therapeutics said EDG-15400 has demonstrated improvements in diastolic function in preclinical models and is being developed to potentially improve cardiac relaxation in patients with HFpEF.
The company will also present the EQUINOX-HFpEF trial design and Phase 1 data for EDG-15400 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing therapies for cardiovascular and cardiometabolic diseases, including hypertrophic cardiomyopathy and heart failure.
Currently, EWTX is trading at $38.50, down 2.70%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
American Airlines To Expand Starlink Connectivity To More Than 1000 Mainline Aircraft
October 08, 2026 11:57 ET
No Evidence Siberia Lab Worker Died Of Plague, Russia Tells WHO
October 08, 2026 10:10 ET
Canadian Author Anne Carson Wins Nobel Prize In Literature
October 08, 2026 09:42 ET
U.S. Jobless Claims Unexpectedly Dip From Upwardly Revised Level
October 08, 2026 09:16 ET
Nearly 70 Million Children Now Have A Trump Account: White House
October 08, 2026 08:27 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down
By
RTTNews Staff Writer
✉
Published:
10/8/2026 2:02 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Edgewise Therapeutics (
EWTX
) announced that the first patient has been dosed in the Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) and a left ventricular ejection fraction of at least 50%.
EDG-15400 is an investigational oral, selective cardiac sarcomere modulator designed to address impaired cardiac relaxation, a key feature of HFpEF that contributes to symptoms and disease burden.
The multicenter, randomized, double-blind, placebo-controlled trial is expected to enroll approximately 90 adults aged 30 to 84 with HFpEF and New York Heart Association class II or III symptoms.
Participants will receive once-daily oral doses of 25 mg or 50 mg of EDG-15400, or placebo, for up to 12 weeks. The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics.
Edgewise Therapeutics said EDG-15400 has demonstrated improvements in diastolic function in preclinical models and is being developed to potentially improve cardiac relaxation in patients with HFpEF.
The company will also present the EQUINOX-HFpEF trial design and Phase 1 data for EDG-15400 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing therapies for cardiovascular and cardiometabolic diseases, including hypertrophic cardiomyopathy and heart failure.
Currently, EWTX is trading at $38.50, down 2.70%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
U.S. Stocks Giving Back Ground Following Recent Strength
October 07, 2026 11:01 ET
Profit Taking May Contribute To Initial Pullback On Wall Street
October 07, 2026 08:57 ET
U.S. Stocks May Move Back To The Upside In Early Trading
September 29, 2026 08:54 ET
View More
October 2026 FDA Decisions: 4 Key Drug Approvals Biotech Investors Should Watch
September 28, 2026 06:25 ET
Every month, the FDA issues decisions on drug approvals — and for biotech investors, these dates are important milestones for the companies and patients involved. In this video, we highlight five key FDA decisions scheduled for October 2026, covering potential approvals and expanded indications across oncology, rare diseases, ophthalmology, and chronic hepatitis B.
View More Videos
RELATED NEWS
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock Down
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
American Airlines To Expand Starlink Connectivity To More Than 1000 Mainline Aircraft
October 08, 2026 11:57 ET
No Evidence Siberia Lab Worker Died Of Plague, Russia Tells WHO
October 08, 2026 10:10 ET
Canadian Author Anne Carson Wins Nobel Prize In Literature
October 08, 2026 09:42 ET
U.S. Jobless Claims Unexpectedly Dip From Upwardly Revised Level
October 08, 2026 09:16 ET
Nearly 70 Million Children Now Have A Trump Account: White House
October 08, 2026 08:27 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
ISIS-inspired Teenager Who Plotted Mass-Shooting At Mall Of America Arrested
October 08, 2026 07:39 ET
British Consulate In East Jerusalem Not Closing, But Renamed As UK Mission
October 08, 2026 07:21 ET
Istanbul Overtakes London Heathrow As World's Most-connected Airport
October 08, 2026 07:00 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Fed Minutes Reveal Officials Expect Another Rate Hike This Year
October 07, 2026 14:23 ET
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
October 07, 2026 12:14 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Applied Digital Secures Access To 1 GW Power Capacity In Finland
October 06, 2026 15:07 ET
Google's Fitbit Edge Tracker May Cost Around $180 With 7-Day Battery Life
October 06, 2026 18:17 ET
CD&R And McKesson To Acquire Option Care Health
October 06, 2026 08:23 ET
Emera, Canadian Utilities To Merge In C$72 Bln Deal
October 06, 2026 07:23 ET
Constellation Acquires SpikeAde For $75 Mln; Shares Down
October 06, 2026 17:22 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
PepsiCo Recalls Gatorade In 37 States Over Undeclared Dyes
October 05, 2026 18:04 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Nexus Advanced Technologies Signs Exclusivity For $500 Mln Defense Tech Reverse Merger
October 06, 2026 08:31 ET
Advanced Drainage Systems To Acquire StormTrap For $530 Mln
October 05, 2026 07:08 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Manufacturing Campus
October 03, 2026 10:21 ET
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 03, 2026 09:12 ET
IRhythm Begins Notifying Patients Following Review Of Cybersecurity Incident
October 04, 2026 03:07 ET
FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL
October 03, 2026 10:42 ET
CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
October 04, 2026 21:10 ET
Bayer To Invest $2.2 Bln In Ohio Pharma Site, To Create 2,100 Jobs
October 03, 2026 11:03 ET
AkzoNobel To Sell Southeast Asia Decorative Paints Business To Nippon Paint In $1.35 Bln Deal
October 04, 2026 21:49 ET
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
October 04, 2026 01:40 ET
Kaneko Seeds Co Ltd Reports Rise In Q1 Bottom Line
October 05, 2026 00:33 ET
FAA Reportedly Finds Boeing 737 Max Software Issue Poses No Safety Risk
October 04, 2026 10:53 ET
Skanska Enters Contract For New High School Project In Renton
October 05, 2026 02:05 ET
Oracle Invests $10 Mln To Support Nashville Symphony's Recovery And Restore Operations
October 04, 2026 20:44 ET
Editors Pick
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Gias Foods Recalls Bettergoods Pasta Sold At Walmart Over Listeria Risk
October 02, 2026 08:47 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ca44afbb16· 2026-10-09 02:16 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前